24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Schizophrenia
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:47
OpenAI hit pause, attackers haven’t. Here’s what security leaders must do next
16:02
Claude Code creator's prompting formula: Say what you want and let AI figure out the rest
15:51
U.S. Army deploys Elbit's Iron Fist defense system against missiles and drones
15:30
Teva gets FDA green light for second long-acting schizophrenia drug
More stories
Buzz
Most popular
Daily
Weekly
1
Nvidia hits record $5.65 trillion as SpaceX seeks $40 billion to buy its AI chips
2
Israel loses $1 billion Apache deal after failing to find $288 million in funding
3
Nikesh Arora sees 40 companies racing to secure AI agents. At least 20 are Israeli
4
Oracle is cutting jobs worldwide. In Israel, it is still hiring
5
Israeli startup raises $5 million to rethink one of surgery's most invasive procedures
More news
Schizophrenia
1 stories about Schizophrenia
Teva gets FDA green light for second long-acting schizophrenia drug
09.10.26
|
CTech
Weltruza follows the 2023 approval of Uzedy, extending Teva's partnership with France's Medincell as it seeks to build new sources of branded drug revenue.